1. Home
  2. JELD vs TNXP Comparison

JELD vs TNXP Comparison

Compare JELD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.80

Market Cap

152.5M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$12.00

Market Cap

169.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
TNXP
Founded
1960
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
169.8M
IPO Year
2016
2008

Fundamental Metrics

Financial Performance
Metric
JELD
TNXP
Price
$1.80
$12.00
Analyst Decision
Hold
Analyst Count
6
0
Target Price
$3.43
N/A
AVG Volume (30 Days)
1.4M
539.5K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
$3,211,181,000.00
$13,107,000.00
Revenue This Year
N/A
$558.11
Revenue Next Year
$2.06
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$0.93
$10.03
52 Week High
$6.98
$69.65

Technical Indicators

Market Signals
Indicator
JELD
TNXP
Relative Strength Index (RSI) 51.38 47.73
Support Level $1.64 $10.03
Resistance Level $2.15 $12.78
Average True Range (ATR) 0.19 0.91
MACD -0.03 0.08
Stochastic Oscillator 36.36 68.31

Price Performance

Historical Comparison
JELD
TNXP

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: